Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the next CEO Corner segment has been published on the Company's website.
新澤西州普林斯頓，2024年12月23日（環球新聞通訊社）-- Sonnet BioTherapeutics Holdings, Inc.（公司或Sonnet）（納斯達克：SONN），一家開發靶向免疫治療藥物的臨牀階段公司，今天宣佈下一個CEO角落已經發佈在 公司網站上發佈.
As part of the CEO Corner segment, Pankaj Mohan, Ph.D., Founder and Chief Executive Officer of Sonnet, highlighted the Company's key accomplishments for calendar year 2024 and the targeted value-driving milestones in calendar year 2025.
在首席執行官角落的內容中，Sonnet的創始人兼首席執行官Pankaj Mohan博士強調了公司在2024日歷年度的主要成就以及2025日歷年度的目標價值驅動里程碑。
The CEO Corner is now accessible on the Company's website here. Segments on the CEO Corner platform will be accessible on the Company's website () for 90 days.
首席執行官角落現在可以在公司的網站上訪問。 這裏在CEO Corner平台上的版塊將在公司官網上可訪問（）爲期90天。
About Sonnet BioTherapeutics Holdings, Inc.
關於Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Sonnet BioTherapeutics是一家專注於腫瘤學的生物技術公司，擁有創新生物藥物單功能或雙功能作用的專有平台。該技術被稱爲FHAb（全人類白蛋白結合），利用全人類單鏈抗體片段（scFv）與人血清白蛋白（HSA）結合並"搭便車"以交通至目標組織。Sonnet的FHAb被設計爲專門靶向腫瘤和淋巴組織，具有改善的治療窗，以優化免疫調節生物藥物的安全性和有效性。FHAb是增強一系列大分子治療類別（包括細胞因數、肽、抗體和疫苗）的模塊化即插即用結構的基礎。
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
SONN@jtcir.com
投資者關係聯繫：
JTC團隊，有限責任公司
詹妮娜·托馬斯
908.824.0775
SONN@jtcir.com
譯文內容由第三人軟體翻譯。
